Tratamiento de la insuficiencia cardiaca: la cuenta atrás empieza en el momento del diagnóstico

Clinical trials have found that sacubitril–valsartan is effective in reducing the risk of hospitalization and death from heart failure and real-life data have confirmed the drug combination’s effectiveness and safety. Moreover, early use during hospitalization, in both patients with de novo heart failure and previously untreated patients, also appears to be safe and is recommended for simplifying patient management and easing transitional care. In addition, sacubitril-valsartan has a beneficial effect on cardiac remodeling, as demonstrated by the results of the PROVE-HF study, which is greater with an early onset and at higher doses in observational studies.

Supplement information: this article is part of a supplement entitled “Questions on a new era for heart failure treatment” which is sponsored by Novartis